As many as 20,000 people in the UK are going to be given medical cannabis as part of a new study aiming to create the largest body of evidence on the drug’s clinical effects.
The trial, named Project Twenty21, will look at the impact of medical cannabis on seven conditions: anxiety disorder, chronic pain, epilepsy, multiple sclerosis (MS), post-traumatic stress disorder, substance abuse and Tourette’s syndrome. It is spearheaded by Professor David Nutt who runs Drug Science, the leading independent scientific body on drugs in the UK, and is backed by the Royal College of Psychiatrists. Researchers are aiming to enroll 20,000 patients by the end of 2021.
Medical cannabis was legalised last year in the UK, but only a handful of patients have been prescribed it since. The National Institute for Health and Care Excellence (NICE) has told doctors not to prescribe it on the NHS as there is not enough evidence it works. This has left people having to find a doctor who will prescribe it privately, and pay a hefty sum for it, or risk criminal prosecution by sourcing the drug illegally.
A positive outcome in the study would make a powerful case for funding from the NHS for medical cannabis.
You can register your interest to take part in the study by clicking here.
Source MS-UK 07/11/2019